[1]唐世英 肖若陶 郝一昌 邱敏 肖春雷*,张树栋*.经皮保留肾脏手术治疗上尿路尿路上皮癌11例报告[J].中国微创外科杂志,2024,01(12):809-814.
　Tang Shiying,Xiao Ruotao,Hao Yichang,et al.Percutaneous Kidneysparing Surgery for Upper Tract Urothelial Carcinoma: Report of 11 Cases[J].Chinese Journal of Minimally Invasive Surgery,2024,01(12):809-814.
点击复制

经皮保留肾脏手术治疗上尿路尿路上皮癌11例报告()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2024年12期
页码:
809-814
栏目:
短篇论著
出版日期:
2024-12-25

文章信息/Info

Title:
Percutaneous Kidneysparing Surgery for Upper Tract Urothelial Carcinoma: Report of 11 Cases
作者:
唐世英 肖若陶 郝一昌 邱敏 肖春雷*; 张树栋*
(北京大学第三医院泌尿外科，北京100191)
Author(s):
Tang Shiying;  Xiao Ruotao;  Hao Yichang;  et al.
Department of Urology, Peking University Third Hospital, Beijing 100191, China
关键词:
经皮保留肾脏手术; 上尿路尿路上皮癌
Keywords:
Percutaneous kidneysparing surgery; Upper tract urothelial carcinoma
文献标志码:
A
摘要:
目的探讨经皮保留肾脏手术(percutaneous kidneysparing surgery，PCKSS)治疗上尿路尿路上皮癌(upper tract urothelial carcinoma，UTUC)的效果。方法2018年1月~2023年12月我们对11例UTUC行PCKSS，在常规建立经皮肾工作通道后，经肾镜置入激光光纤或者等离子电切装置，沿肿瘤边缘0.5 cm将肿瘤逐块切除。结果11例PCKSS均顺利完成，3例为多发肿瘤。手术时间75~216 min，中位数150 min。术中出血量20~400 ml，中位数150 ml。术后病理诊断：9例高级别UTUC，其中G2 3例，G3 6例，pTa期5例，pT1期4例；2例术前输尿管镜活检病理为pTa期高级别UTUC，PCKSS术中因取材表浅，组织烧灼明显，未见确切癌。术后住院时间(6.9±2.6)d。11例随访2~55个月，中位数12个月，复发4例，其中死亡2例，无复发生存7例。结论PCKSS治疗肾功能不全的UTUC具有一定的应用价值，但术前需要谨慎选择合适的患者，术后严格定期随访。
Abstract:
ObjectiveTo analyze the clinical efficacy of percutaneous kidneysparing surgery (PCKSS) for the treatment of upper tract urothelial carcinoma (UTUC).MethodsA retrospective analysis was conducted on clinical data and oncological characteristics of 11 cases of UTUC treated with PCKSS at our hospital from January 2018 to December 2023. After establishing a percutaneous renal working channel, a laser fiber or plasma resection device was inserted through the nephroscope to remove the tumor piece by piece along the edge of the tumor by 0.5 cm.ResultsAll the 11 cases of PCKSS surgery were successfully completed, with 3 cases having multiple tumors. The surgical time was 75-216 min (median, 150 min), and the intraoperative bleeding volume was 20-400 ml (median, 150 ml). Postoperative pathological diagnosis showed 9 cases of highgrade UTUC, including 3 cases of G2 grade and 6 cases of G3 grade, with 5 cases in pTa phase and 4 cases in pT1 phase. In 2 cases with preoperative ureteroscopic biopsy showing highgrade pTa phase UTUC, no definite tumor was found during the PCKSS due to shallow sampling and obvious tissue burning. The average postoperative hospitalization time was (6.9±2.6)d. The 11 cases were followed up for 2-55 months (median, 12 months), and there were 4 cases of recurrence, including 2 deaths, and 7 cases of recurrence free survival.ConclusionsPCKSS has certain application value for treating UTUC with renal insufficiency. However, it is necessary to carefully select suitable patients before surgery, and strict and regular followup is required after surgery.

参考文献/References:

[1]Rouprêt M, Babjuk M, Burger M, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol,2021,79(1):62-79.
[2]黄健,张旭,主编.中国泌尿外科和男科疾病诊断治疗指南.北京：科学出版社,2022.272-273.
[3]Weight CJ, Larson BT, Fergany AF, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol,2010,183(4):1317-1323.
[4]Seisen T, Peyronnet B, DominguezEscrig JL, et al. Oncologic outcomes of kidneysparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: A systematic review by the EAU nonmuscle invasive bladder cancer guidelines panel. Eur Urol,2016,70(6):1052-1068.
[5]Park BH, Jeon SS. Endoscopic management of upper urinary tract urothelial carcinoma. Korean J Urol,2013,54(7):426-432.
[6]Moch H, Amin MB, Berney DM, et al. The 2022 world health organization classification of tumours of the urinary system and male genital organspart a: renal, penile, and testicular tumours. Eur Urol,2022,82(5):458-468.
[7]Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a populationbased to a more “personalized” approach to cancer staging. CA Cancer J Clin,2017,67(2):93-99.
[8]Ham WS, Park JS, Jang WS, et al. Nephronsparing approaches in upper tract urothelial carcinoma: current and future strategies. Biomedicines,2022,10(9):2223.
[9]Sarmah PB, Ehsanullah SA, Sarmah BD. Longterm followup and outcomes of percutaneous nephronsparing surgery for upper tract urothelial carcinoma. Indian J Urol,2020,36(4):276-281.
[10]Deligne E, Colombel M, Badet L, et al. Conservative management of upper urinary tract tumors. Eur Urol,2002,42(1):43-48.
[11]Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: longterm followup. J Urol,2003,169(3):925-930.
[12]Lam JS, Gupta M. Ureteroscopic management of upper tract transitional cell carcinoma. Urol Clin North Am,2004,31(1):115-128.
[13]Puech P, Rouprêt M, RenardPenna R, et al. Imaging of urothelial carcinomas of the upper tract: state of the art review for the yearly scientific report of the national french association of urology. Prog Urol,2014,24(15):987-999.
[14]Wang JK, Tollefson MK, Krambeck AE, et al. High rate of pathologic upgrading at nephroureterectomy for upper tract urothelial carcinoma. Urology,2012,79(3):615-619.
[15]Huang GL, Luo HL, Chiang PH. Does preoperative percutaneous nephrostomy insertion worsen uppertract urothelial cancer oncological outcome? A retrospective single center study. BMC Urol,2019,19(1):50.
[16]Grosso AA, Sessa F, Campi R, et al. Intraoperative and postoperative surgical complications after ureteroscopy, retrograde intrarenal surgery, and percutaneous nephrolithotomy: a systematic review. Minerva Urol Nephrol,2021,73(3):309-332.
[17]Sabnis RB, Ganesamoni R, Sarpal R. Miniperc: what is its current status? Curr Opin Urol,2012,22(2):129-133.
[18]王大明,丁德茂,谢栋栋,等.超声引导联合内镜监视建立经皮肾镜工作通道.中国微创外科杂志,2021,21(12):1129-1132.
[19]Gadzinski AJ, Roberts WW, Faerber GJ, et al. Longterm outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol,2010,183(6):2148-2153.
[20]Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy? Urology,2009,73(1):27-31.
[21]Foerster B, D′Andrea D, Abufaraj M, et al. Endocavitary treatment for upper tract urothelial carcinoma: a metaanalysis of the current literature. Urol Oncol,2019,37(7):430-436.
[22]Haddad M, Cloutier J, Cornu JN, et al. Immediate nephroureterectomy or after attempting conservative treatment, on elective indications, for upper urinary tract urothelial carcinoma: comparison of the pathology reports on a retrospective monocentric study. J Endourol,2015,29(8):969-973.
[23]PintoFilho VA, Nascimento E, Cunha APL, et al. Malignancy diseases in kidney transplantation, clinical outcomes, patient, and allograft survival: a casecontrol study. Transplant Proc,2022,54(5):1253-1261.
[24]Barama A, StLouis G, Nicolet V, et al. Renal cell carcinoma in kidney allografts: a case series from a single center. Am J Transplant,2005,5(12):3015-3018.

备注/Memo

备注/Memo:
*通讯作者，Email:xiaochunleixcl@163.com(肖春雷)，shootong@163.com(张树栋)
更新日期/Last Update: 2025-02-27